139 related articles for article (PubMed ID: 12209598)
1. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR
Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.
Rutkowski P; Van Glabbeke M; Rankin CJ; Ruka W; Rubin BP; Debiec-Rychter M; Lazar A; Gelderblom H; Sciot R; Lopez-Terrada D; Hohenberger P; van Oosterom AT; Schuetze SM; ;
J Clin Oncol; 2010 Apr; 28(10):1772-9. PubMed ID: 20194851
[TBL] [Abstract][Full Text] [Related]
3. Establishment and characterization of NCC-DFSP5-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line.
Ono T; Noguchi R; Osaki J; Akiyama T; Adachi Y; Kojima N; Toda Y; Fukushima S; Yoshimatsu Y; Yoshida A; Kawai A; Kondo T
Hum Cell; 2024 May; 37(3):854-864. PubMed ID: 38372888
[TBL] [Abstract][Full Text] [Related]
4. A case report of abdominal metastatic dermatofibrosarcoma protuberans misdiagnosed as gastrointestinal stromal tumor.
Deng M; Liu Q; Ren L; Yuan W; Xu C; Hou Y
Diagn Pathol; 2024 Feb; 19(1):41. PubMed ID: 38388419
[TBL] [Abstract][Full Text] [Related]
5. COL1A1::PDGFB fusion-associated uterine fibrosarcoma: A case report and review of the literature.
Rota S; Franza A; Fabbroni C; Paolini B; Greco FG; Alessi A; Padovano B; Casali P; Sanfilippo R
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1969. PubMed ID: 38279510
[TBL] [Abstract][Full Text] [Related]
6. Establishment and characterization of NCC-DFSP4-C1: a novel cell line from a patient with dermatofibrosarcoma protuberans having the fibrosarcomatous transformation.
Akiyama T; Yoshimatsu Y; Noguchi R; Sin Y; Osaki J; Ono T; Adachi Y; Tsuchiya R; Toda Y; Ogura K; Kojima N; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2023 Nov; 36(6):2187-2194. PubMed ID: 37490236
[TBL] [Abstract][Full Text] [Related]
7. Dermatofibrosarcoma protuberans: from translocation to targeted therapy.
Noujaim J; Thway K; Fisher C; Jones RL
Cancer Biol Med; 2015 Dec; 12(4):375-84. PubMed ID: 26779374
[TBL] [Abstract][Full Text] [Related]
8. Multi-omic profiling and real time ex vivo modelling of imatinib-resistant dermatofibrosarcoma protuberans with fibrosarcomatous transformation.
Chan JY; Lee ECY; Li Z; Lee JY; Lim AH; Poon E
Hum Cell; 2023 Nov; 36(6):2228-2236. PubMed ID: 37610680
[TBL] [Abstract][Full Text] [Related]
9. A Multicenter Virtual Multidisciplinary Sarcoma Case Conference Improves Outcome for a Rare Soft Tissue Sarcoma (Dermatofibrosarcoma Protuberans).
Chang AL; Kwak HV; Pan M; Peng PD; Morse LJ; Chang CK
Am Surg; 2023 Dec; 89(12):5240-5245. PubMed ID: 36441590
[TBL] [Abstract][Full Text] [Related]
10. Multiple primary dermatofibrosarcoma protuberans tumors in a single patient with chromosomal microarray analysis: A case report and review.
Durgin JS; Whittington CP; Joseph M; Harms PW; Andea AA; Pedersen EA; Smith EH; Harms KL
J Cutan Pathol; 2024 Mar; ():. PubMed ID: 38548658
[TBL] [Abstract][Full Text] [Related]
11. Impact of human adipose tissue-derived stem cells on dermatofibrosarcoma protuberans cells in an indirect co-culture: an in vitro study.
Yuan Z; Zhu Z; Zhu F; Ding F; Wang Y; Wang X; Luo X; Yang J; Liu F; Sun D
Stem Cell Res Ther; 2021 Aug; 12(1):440. PubMed ID: 34362454
[TBL] [Abstract][Full Text] [Related]
12. A Case Report of Dermatofibrosarcoma Protuberans and Refractory Hypomagnesemia: Unveiling a Paraneoplastic Syndrome.
Chaudhari P; Sawant R; Reddy N; Kumar S; Acharya S
Cureus; 2024 Mar; 16(3):e55301. PubMed ID: 38562367
[TBL] [Abstract][Full Text] [Related]
13. Extensive analysis of 59 sarcoma-related fusion genes identified pazopanib as a potential inhibitor to COL1A1-PDGFB fusion gene.
Hirose T; Ikegami M; Kojima S; Yoshida A; Endo M; Shimada E; Kanahori M; Oyama R; Matsumoto Y; Nakashima Y; Kawai A; Mano H; Kohsaka S
Cancer Sci; 2023 Oct; 114(10):4089-4100. PubMed ID: 37592448
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection.
Rutkowski P; Dębiec-Rychter M; Nowecki Z; Michej W; Symonides M; Ptaszynski K; Ruka W
J Eur Acad Dermatol Venereol; 2011 Mar; 25(3):264-70. PubMed ID: 20569296
[TBL] [Abstract][Full Text] [Related]
15. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate.
Labropoulos SV; Fletcher JA; Oliveira AM; Papadopoulos S; Razis ED
Anticancer Drugs; 2005 Apr; 16(4):461-6. PubMed ID: 15746584
[TBL] [Abstract][Full Text] [Related]
16. Unraveling intratumoral complexity in metastatic dermatofibrosarcoma protuberans through single-cell RNA sequencing analysis.
Ge LL; Wang ZC; Wei CJ; Huang JX; Liu J; Gu YH; Wang W; Li QF
Cancer Immunol Immunother; 2023 Dec; 72(12):4415-4429. PubMed ID: 37938367
[TBL] [Abstract][Full Text] [Related]
17. Molecular targeted therapy for advanced or metastatic soft tissue sarcoma.
Yuan J; Li X; Yu S
Cancer Control; 2021; 28():10732748211038424. PubMed ID: 34844463
[TBL] [Abstract][Full Text] [Related]
18. Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis.
Sparber-Sauer M; Orbach D; Navid F; Hettmer S; Skapek S; Corradini N; Casanova M; Weiss A; Schwab M; Ferrari A
Br J Cancer; 2021 May; 124(10):1637-1646. PubMed ID: 33723397
[TBL] [Abstract][Full Text] [Related]
19. [Systemic therapy of sarcomas : New biomarkers and therapeutic strategies].
Bauer S; Dirksen U; Schildhaus HU
Pathologe; 2019 Jul; 40(4):436-442. PubMed ID: 31243550
[TBL] [Abstract][Full Text] [Related]
20. Abscopal Effect of Radiotherapy in Imatinib-resistant Dermatofibrosarcoma Protuberans.
Agyeman MB; Vanderpuye VD; Yarney J
Cureus; 2019 Jan; 11(1):e3857. PubMed ID: 30899608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
